Latest New Zealand News

Foley Wines reported a 258% surge in net profit for FY2026 despite a 5.4% decline in bottled sales revenue, driven by a premiumisation strategy and cost controls.

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Mirrabooka Investments posted a 63.6% profit increase to $13 million for FY26 but saw its portfolio return lag the benchmark. The company declared a 14 cents fully franked dividend and welcomed Alison Gibson as new CEO following Mark Freeman's retirement.

Kip McGrath Education Centres reversed prior losses with a $2.5 million profit in FY26 despite a 4.3% revenue dip driven by franchise consolidation and foreign exchange headwinds. The company declared a special dividend and faces an unsolicited $0.73 per share takeover offer.

Dicker Data’s first half FY26 results reveal a sharp 54% jump in net profit, driven by strong revenue growth across software and AI infrastructure, prompting an upgraded full-year forecast.

Harvey Norman Holdings reported a 10.9% rise in profit before tax excluding one-off adjustments, driven by international retail growth and a robust property portfolio. The company declared a fully franked 13 cent final dividend, maintaining a strong balance sheet with conservative gearing.

PEXA Group delivered a solid FY26 with 7% revenue growth and a return to profitability, while facing a regulatory pricing review that could reshape its future investment capacity.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

Patrys has cleared a key regulatory hurdle with Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202, aiming to start dosing healthy volunteers this quarter.

Talius Group’s HY2026 results reveal a strategic pivot towards higher-margin software subscriptions, with gross margin surging to 51% despite a 19% revenue dip due to hardware deployment timing. Active subscriptions topped 53,200, underpinning a $3.26 million ARR, while cash burn shrank dramatically.

Shine Justice Ltd reported a modest 2.3% revenue increase to $209.2 million for FY26, alongside a striking 1,578% jump in net profit after tax to $9.6 million. The company declared a fully franked final dividend of 2.5 cents per share, signalling confidence amid ongoing investments in technology and international expansion.